In the present study, I delineated biological functions and pathways specifically enriched in metastatic breast cancer and demonstrated that CCNA2, CENPN, DEPDC1, TTK, ABAT, LRIG1, PGR, KIF2C, and ESR1 may serve as biomarkers to predict clinical outcomes of breast cancer patients. This evidence concerns the gene DEPDC1 and breast carcinoma.